The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
Cisplatin and either capecitabine or 5-fluorouracil
ChT
HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction in patients who have not received prior anti-cancer treatment for their metastatic disease
Gastrointestinal Cancers
Stomach or gastroesophageal junction cancer
HER2+
ToGA
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Ivosidenib
-
Placebo
For adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.
Gastrointestinal Cancers
Cholangiocarcinoma
IDH1
ClarIDHy
3
PRELIMINARY SCORE
OS
7
ADJUSTMENTS
FINAL SCORE
F1
3
Mobocertinib
-
Single arm (Phase I/II)
Locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, with progression on or after platinum-based ChT
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+ exon 20 insertion mutations
Study 101
2
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
4
Tisotumab vedotin
-
Single arm (Phase II)
Progression on or after platinum-based ChT
Gynaecological Malignancies
Cervical Cancer
-
innovaTV 204
2
PRELIMINARY SCORE
OS
7
ADJUSTMENTS
FINAL SCORE
F1
4
Trifluridine/Tipiracil (TAS-102)
Best supportive care
Placebo
Treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agents
Gastrointestinal Cancers
Colorectal Cancer
-
RECOURSE
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Pembrolizumab
-
ChT ((5-fluorouracil–based therapy with or without bevacizumab or cetuximab)
First‑line treatment of metastatic microsatellite instability‑high (MSI‑H) or mismatch repair deficient (dMMR) colorectal cancer in adults.
Gastrointestinal Cancers
Colorectal Cancer
dMMR or MSI-H
KEYNOTE-177
4
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
2
Cabozantinib
-
Placebo
Treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy
Endocrine Tumours
Thyroid cancer - differentiated
-
COSMIC-311
2
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
4
Pralsetinib
-
Single arm (Phase I/II
Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant MTC who require systemic therapy
Endocrine Tumours
Thyroid Cancer - medullary
RET-mutant
ARROW
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Pralsetinib
-
Single arm (Phase I/II)
Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive or mutant thyroid cancer who require systemic therapy and who are RAI-refractory
Endocrine Tumours
Thyroid cancer - differentiated
RET fusion-positive
ARROW
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Atezolizumab
-
Best supportive care
Adjuvant treatment following resection and platinum-based ChT for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥1% of tumor cells
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥1%
IMpower010
A
ADJUSTMENTS
FINAL SCORE
F1
1
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Treatment Setting
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
esmo.mcbs.table.heading.visualisation
esmo.mcbs.table.heading.visualisation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.